| Revision as of 10:29, 26 October 2011 editLouisajb (talk | contribs)Extended confirmed users4,402 edits added chembl id← Previous edit | Revision as of 10:40, 26 October 2011 edit undoCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report...Next edit → | ||
| Line 1: | Line 1: | ||
| {{Drugbox | {{Drugbox | ||
| | Verifiedfields = changed | |||
| | Watchedfields = changed | | Watchedfields = changed | ||
| | verifiedrevid = 424715425 | | verifiedrevid = 424715425 | ||
| | IUPAC_name = 8-chloro-3-(methoxymethyl)-5-methyl-4H-imidazobenzodiazepin-6-one | | IUPAC_name = 8-chloro-3-(methoxymethyl)-5-methyl-4H-imidazobenzodiazepin-6-one | ||
| | image = PWZ-029_structure.png | | image = PWZ-029_structure.png | ||
| | ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| | ChEMBL = 512572 | | ChEMBL = 512572 | ||
| Line 25: | Line 27: | ||
| <!--Identifiers--> | <!--Identifiers--> | ||
| | CAS_number_Ref = {{cascite|correct|??}} | |||
| | CAS_number = | | CAS_number = | ||
| | ATC_prefix = | | ATC_prefix = | ||
Revision as of 10:40, 26 October 2011
Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| PubChem CID | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H14ClN3O2 |
| Molar mass | 291.732 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
| (what is this?) (verify) | |
PWZ-029 is a benzodiazepine derivative drug with nootropic effects. It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.
See also
References
- Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Research. 2008 May 7;1208:150-9. doi:10.1016/j.brainres.2008.02.020 PMID 18394590
| Psychostimulants, agents used for ADHD, and nootropics (N06B) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| N06BA Centrally acting sympathomimetics | |||||||||
| N06BC Xanthine derivatives | |||||||||
| N06BX Other psychostimulants and nootropics | |||||||||
| |||||||||
 | This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |